首页> 美国卫生研究院文献>Clinical and Molecular Hepatology >Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B

【2h】

Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B

机译：接受口服抗病毒药物治疗的慢性乙型肝炎初治患者肝癌发生风险评分模型

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background/AimsThis study aimed to develop and validate a risk prediction model for the development of hepatocellular carcinoma (HCC) in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B (CHB).

机译：背景/目的本研究旨在开发和验证未接受过慢性乙型肝炎（CHB）口服抗病毒治疗的初治患者肝细胞癌（HCC）发生的风险预测模型。

著录项

期刊名称 Clinical and Molecular Hepatology
作者
Won Sohn; Ju-Yeon Cho; Ji Hoon Kim; Jung Il Lee; Hyung Joon Kim; Min-Ah Woo; Sin-Ho Jung; Yong-Han Paik;
展开▼
作者单位

展开▼
年(卷),期 2017(23),2
年度 2017
页码 170–178
总页数 9
原文格式 PDF
正文语种
中图分类分子生物学;
关键词
Chronic hepatitis B Hepatocellular carcinoma Assessment Risk Antiviral drugs;

机译：慢性乙型肝炎;肝细胞癌;评估;风险;抗病毒药物;

相似文献

外文文献
中文文献
专利

1. Development and Validation of a Risk Score for Hepatocellular Carcinoma in Chronic Hepatitis B Patients under Antiviral Treatment [J] . Hsu Yao-Chun, Yip Terry Cheuk-Fung, Ho Hsiu-Jon, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：抗病毒治疗慢性乙型肝炎患者肝细胞癌风险分数的开发与验证
2. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. [J] . Papatheodoridis GV, Manolakopoulos S, Touloumi G, Gut: Journal of the British Society of Gastroenterology . 2011,第8期

机译：从拉米夫定单一疗法开始，接受口服抗病毒药物的HBeAg阴性慢性乙型肝炎肝硬化患者接受病毒学抑制不能阻止肝细胞癌的发展：全国HEPNET的结果。希腊队列研究。
3. Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy [J] . The Journal of Infectious Diseases . 2020,第3期

机译：亚太地区肝脏联盟对HBV风险评分的真实效力，用于预测口腔抗病毒治疗慢性乙型肝炎患者肝细胞癌的肝细胞癌
4. Betatrophin Expression in Chronic Hepatitis C Patients: Does Contribute to Liver Injury-linked Metabolic Syndrome and Hepatocellular Carcinoma Development? [C] . Hendra Susanto, Nan-Shan Liou, Bogi Pratomo, International Conference on Life Sciences and Technology . 2020

机译：慢性丙型肝炎患者的BERATROPHIN表达：是否有助于肝损伤链接代谢综合征和肝细胞癌发育？
5. The meaning of adherence among veterans receiving pegylated interferon and ribavirin antiviral treatment for chronic hepatitis C. [D] . Phillips, Frances Hinshaw. 2011

机译：接受聚乙二醇干扰素和利巴韦林抗病毒治疗的慢性丙型肝炎退伍军人依从性的含义。
6. Original research: Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale propensity score analysis [O] . Sung Won Lee, Jung Hyun Kwon, Hae Lim Lee, -1

机译：原始研究：替诺福韦和恩替卡韦在韩国未接受过治疗的慢性乙型肝炎患者中对肝细胞癌风险和死亡率的比较：大规模倾向得分分析
7. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B [O] . Won Sohn, Ju-Yeon Cho, Ji Hoon Kim, 2017

机译：接受口服抗病毒治疗慢性乙型肝炎的初治患者肝细胞癌发展的风险评分模型

Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B

摘要

著录项

相似文献

相关主题

期刊订阅